Oral tablets with canagliflozin, an SGLT2 inhibitor, designed for type 2 diabetes therapy. Produced by generic and originator pharmaceutical firms for distribution to healthcare distributors, clinics, and hospital pharmacies. Sourced by procurement teams for outpatient and inpatient diabetes treatment protocols.